<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35613082</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>5</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>A phase II open label clinical study of the safety, tolerability and efficacy of ILB&#xae; for Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>e0267183</StartPage><MedlinePgn>e0267183</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0267183</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0267183</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Amyotrophic lateral sclerosis (ALS) is an invariably lethal progressive disease, causing degeneration of neurons and muscle. No current treatment halts or reverses disease advance. This single arm, open label, clinical trial in patients with ALS investigated the safety and tolerability of a novel modified low molecular weight dextran sulphate (LMW-DS, named ILB&#xae;) previously proven safe for use in healthy volunteers and shown to exert potent neurotrophic effects in pre-clinical studies. Secondary endpoints relate to efficacy and exploratory biomarkers.</AbstractText><AbstractText Label="METHODS">Thirteen patients with ALS were treated with 5 weekly subcutaneous injections of ILB&#xae;. Safety and efficacy outcome measures were recorded weekly during treatment and at regular intervals for a further 70 days. Functional and laboratory biomarkers were assessed before, during and after treatment.</AbstractText><AbstractText Label="RESULTS">No deaths, serious adverse events or participant withdrawals occurred during or after ILB&#xae; treatment and no significant drug-related changes in blood safety markers were evident, demonstrating safety and tolerability of the drug in this cohort of patients with ALS. The PK of ILB&#xae; in patients with ALS was similar to that seen in healthy controls. The ILB&#xae; injection elicited a transient elevation of plasma Hepatocyte Growth Factor, a neurotrophic and myogenic growth factor. Following the ILB&#xae; injections patients reported increased vitality, decreased spasticity and increased mobility. The ALSFRS-R rating improved from 36.31 &#xb1; 6.66 to 38.77 &#xb1; 6.44 and the Norris rating also improved from 70.61 &#xb1; 13.91 to 77.85 &#xb1; 14.24 by Day 36. The improvement of functions was associated with a decrease in muscle atrophy biomarkers. These therapeutic benefits decreased 3-4 weeks after the last dosage.</AbstractText><AbstractText Label="CONCLUSIONS">This pilot clinical study demonstrates safety and tolerability of ILB&#xae; in patients with ALS. The exploratory biomarker and functional measures must be cautiously interpreted but suggest clinical benefit and have a bearing on the mechanism of action of ILB&#xae;. The results support the drug's potential as the first disease modifying treatment for patients with ALS.</AbstractText><AbstractText Label="TRIAL REGISTRATION">EudraCT 2017-005065-47.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Logan</LastName><ForeName>Ann</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3215-5042</Identifier><AffiliationInfo><Affiliation>Axolotl Consulting Ltd, Droitwich, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagy</LastName><ForeName>Zsuzsanna</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnes</LastName><ForeName>Nicholas M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belli</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Pietro</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tavazzi</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Basic Biotechnological Sciences, Intensive and Perioperative Clinics, Catholic University of Rome, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazzarino</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Biotechnological Sciences, Division of Medical Biochemistry, University of Catania, Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazzarino</LastName><ForeName>Giacomo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>UniCamillus, Saint Camillus International University of Health Sciences, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruce</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Tikomed AB, Viken, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Persson</LastName><ForeName>Lennart I</ForeName><Initials>LI</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>EudraCT</DataBankName><AccessionNumberList><AccessionNumber>2017-005065-47</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have read the journal&#x2019;s policy and have the following competing interests: LB and AL are paid consultants of Tikomed AB. The authors would like to declare the following patents/patent applications associated with this research: Patents pertaining to this LMW-DS drug have been filed by Tikomed AB (publication number: WO 2016/076780 &#x2013; New dextran sulphate) with LB as a co-inventor ILB&#xae;. LB is a board member of Tikomed AB and receives consultancy payments for work related to the commercial development of ILB&#xae;. AL is affiliated with Axolotl Consulting Ltd. This does not alter our adherence to PLOS ONE policies on sharing data and materials.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>25</Day><Hour>13</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35613082</ArticleId><ArticleId IdType="pmc">PMC9132272</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0267183</ArticleId><ArticleId IdType="pii">PONE-D-21-04468</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Talbott EO, Malek AM, Lacomis D. The epidemiology of amyotrophic lateral sclerosis. Handbook of Clinical Neurology. 2016;138: 225&#x2013;38. Available from: doi: 10.1016/B978-0-12-802973-2.00013-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-802973-2.00013-6</ArticleId><ArticleId IdType="pubmed">27637961</ArticleId></ArticleIdList></Reference><Reference><Citation>Czaplinski A, Yen AA, Simpson EP, Appel SH. Slower disease progression and prolonged survival in contemporary patients with amyotrophic lateral sclerosis. Archives of Neurology. 2006;63: 1139&#x2013;1143. Available from: doi: 10.1001/archneur.63.8.1139</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.63.8.1139</ArticleId><ArticleId IdType="pubmed">16908741</ArticleId></ArticleIdList></Reference><Reference><Citation>Qureshi MM, Hayden D, Urbinelli L, Ferrante K, Newhall K, Myers D, et al.. Analysis of factors that modify susceptibility and rate of progression in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis. 2006;7: 173&#x2013;82. Available from: doi: 10.1080/14660820600640596</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820600640596</ArticleId><ArticleId IdType="pubmed">16963407</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkels&#xf6; C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. Journal of Neurochemistry. 1996;67: 2013&#x2013;18. Available from: doi: 10.1046/j.1471-4159.1996.67052013.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1996.67052013.x</ArticleId><ArticleId IdType="pubmed">8863508</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Henderson RD, David M, McCombe PA. Neurofilaments as biomarkers for amyotrophic lateral sclerosis: A systematic review and meta-analysis. PLoS One. 2016;11: e0164625. Available from: doi: 10.1371/journal.pone.0164625</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0164625</ArticleId><ArticleId IdType="pmc">PMC5061412</ArticleId><ArticleId IdType="pubmed">27732645</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesalingam J, An J, Shaw CE, Shaw G, Lacomis D, Bowser R. Combination of neurofilament heavy chain and complement c# as CSF biomarkers for ALS. Journal of Neurochemistry. 2011;117: 528&#x2013;37. Available from: doi: 10.1111/j.1471-4159.2011.07224.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2011.07224.x</ArticleId><ArticleId IdType="pmc">PMC3076545</ArticleId><ArticleId IdType="pubmed">21418221</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe PA, Henderson RD. The role of immune and inflammatory mechanisms in ALS. Current Molecular Medicine. 2011;11: 246&#x2013;54. Available from: doi: 10.2174/156652411795243450</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156652411795243450</ArticleId><ArticleId IdType="pmc">PMC3182412</ArticleId><ArticleId IdType="pubmed">21375489</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagani MR, Gonzales LE, Uchitel OD. Autoimmunity in amyotrophic lateral sclerosis: past and present. Neurology Research International. 2011;11: 497080. Available from: doi: 10.1155/2011/497080</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2011/497080</ArticleId><ArticleId IdType="pmc">PMC3150148</ArticleId><ArticleId IdType="pubmed">21826267</ArticleId></ArticleIdList></Reference><Reference><Citation>Phani S, Re DB, Przedborski S. (2012). The role of the innate immune system in ALS. Frontiers in Pharmacology. 2012;3: 150. Available from: doi: 10.3389/fphar.2012.00150</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2012.00150</ArticleId><ArticleId IdType="pmc">PMC3418523</ArticleId><ArticleId IdType="pubmed">22912616</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryberg H, An J, Darko S, Lustgarten JL, Jaffa M, Gopalakrishnan V, et al.. (2010). Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics. Muscle &amp; Nerve. 2010;42: 104&#x2013;11. Available from: doi: 10.1002/mus.21683</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.21683</ArticleId><ArticleId IdType="pmc">PMC2975276</ArticleId><ArticleId IdType="pubmed">20583124</ArticleId></ArticleIdList></Reference><Reference><Citation>Vu LT, Bowser R. (2017). Fluid-based biomarkers for amyotrophic lateral sclerosis. Neurotherapeutics. 2017;14: 119&#x2013;34. Available from: doi: 10.1007/s13311-016-0503-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0503-x</ArticleId><ArticleId IdType="pmc">PMC5233638</ArticleId><ArticleId IdType="pubmed">27933485</ArticleId></ArticleIdList></Reference><Reference><Citation>Battaglia G, Bruno V. Metabotropic glutamate receptor involvement in the pathophysiology of amyotrophic lateral sclerosis: new potential drug targets for therapeutic applications. Current Opinion in Pharmacology.2018;38: 65&#x2013;71. Available from: doi: 10.1016/j.coph.2018.02.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2018.02.007</ArticleId><ArticleId IdType="pubmed">29529498</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al.. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541: 481&#x2013;7. Available from: doi: 10.1038/nature21029</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature21029</ArticleId><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryberg H, Askmark H, Persson LI. A double blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: Effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters. Acta Neurologica Scandinavica. 2003;108: 1&#x2013;8. Available from: doi: 10.1034/j.1600-0404.2003.00111.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1600-0404.2003.00111.x</ArticleId><ArticleId IdType="pubmed">12807386</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahia EL, Idrissi N, Bosch S, Ramaglia V, Aronica E, Bass F, et al.. Complement activation at the motor end-plates in amyotrophic lateral sclerosis. Journal of Neuroinflammation. 2016;13: 72. Available from: doi: 10.1186/s12974-016-0538-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-016-0538-2</ArticleId><ArticleId IdType="pmc">PMC4823861</ArticleId><ArticleId IdType="pubmed">27056040</ArticleId></ArticleIdList></Reference><Reference><Citation>Budenholzer L, Cheng CL, Li Y, Hochstrasser M. Proteasome structure and assembly. Journal of Molecular Biology. 2017;429: 3500&#x2013;25. Available from: doi: 10.1016/j.jmb.2017.05.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2017.05.027</ArticleId><ArticleId IdType="pmc">PMC5675778</ArticleId><ArticleId IdType="pubmed">28583440</ArticleId></ArticleIdList></Reference><Reference><Citation>Inobe T, Matouschek A. Paradigms of protein degradation by the proteasome. Current Opinion in Structural Biology. 2014;24: 156&#x2013;64. Available from: doi: 10.1016/j.sbi.2014.02.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sbi.2014.02.002</ArticleId><ArticleId IdType="pmc">PMC4010099</ArticleId><ArticleId IdType="pubmed">24632559</ArticleId></ArticleIdList></Reference><Reference><Citation>Lonnroth I, Oshalim M, Lange S, Johansson E. Interaction of proteasomes and complement C3 assay of antisecretory factor in blood. Journal of Immunoassay and Immunochemistry. 2016;37: 43&#x2013;54. Available from: doi: 10.1080/15321819.2015.1042544</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15321819.2015.1042544</ArticleId><ArticleId IdType="pubmed">25897558</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, Allen K, Oei F. Systemic inflammatory response and neuromuscular involvement amyotrophic lateral sclerosis. Neurology, Neuroimmunology and Neuroinflammation. 2016;3: e244. Available from: doi: 10.1212/NXI.0000000000000244</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000244</ArticleId><ArticleId IdType="pmc">PMC4897985</ArticleId><ArticleId IdType="pubmed">27308305</ArticleId></ArticleIdList></Reference><Reference><Citation>Malaspina M, Puentes F, Amor S. Disease origin and progression in amyotrophic lateral sclerosis: an immunology perspective. International Immunology. 2015;27: 117&#x2013;29. Available from: doi: 10.1093/intimm/dxu099</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/dxu099</ArticleId><ArticleId IdType="pubmed">25344935</ArticleId></ArticleIdList></Reference><Reference><Citation>Milosevic M, Millicevic K, Bosic I, Lavrnja I, Stevanovi&#x107; I, Bijeli&#x107; D, et al.. Immunoglobulins G from sera of amyotrophic lateral sclerosis patients induce oxidative stress system in BV-2 microglial cell line. Frontiers in Immunology. 2017;8: 1619. Available from: doi: 10.3389/fimmu.2017.01619</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01619</ArticleId><ArticleId IdType="pmc">PMC5703705</ArticleId><ArticleId IdType="pubmed">29218049</ArticleId></ArticleIdList></Reference><Reference><Citation>Verber NS, Shepheard SR, Sassani M, McDonough HE, Moore SA, Alix JJP, et al.. Biomarkers in motor neuron disease: A state of the art review. Frontiers in Neurology. 2019;10: 291. Available from: doi: 10.3389/fneur.2019.00291</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00291</ArticleId><ArticleId IdType="pmc">PMC6456669</ArticleId><ArticleId IdType="pubmed">31001186</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazzarino G, Amorini AM, Barnes NM, Bruce L, Mordente A, Lazzarino G, et al.. Low molecular weight dextran sulfate (ILB&#xae;) administration restores brain energy metabolism following severe traumatic brain injury in the rat. Antioxidants. 2020;9(9): 850. Available from: doi: 10.3390/antiox9090850</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox9090850</ArticleId><ArticleId IdType="pmc">PMC7555574</ArticleId><ArticleId IdType="pubmed">32927770</ArticleId></ArticleIdList></Reference><Reference><Citation>von Zur-M&#xfc;hlen B, Lundgren T, Bayman L, Berne C, Bridges N, Eggerman T, et al.. Open randomized multicenter study to evaluate safety and efficacy of low molecular weight sulphated dextran in islet transplantation. Transplantation. 2019;103(3): 630&#x2013;7. Available from: doi: 10.1097/TP.0000000000002425</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000002425</ArticleId><ArticleId IdType="pmc">PMC6389380</ArticleId><ArticleId IdType="pubmed">30211831</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi W, Lee J, Lee J, Lee SH, Kim S. Hepatocyte Growth Factor regulates macrophage transition to the M2 phenotype and promotes murine skeletal muscle regeneration. Frontiers in Physiology. 2019;10: 914. Available from: doi: 10.3389/fphys.2019.00914</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2019.00914</ArticleId><ArticleId IdType="pmc">PMC6672745</ArticleId><ArticleId IdType="pubmed">31404148</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Lee N, Kim S, Lee J, Choi W, Yu SS, et al.. Intramuscular delivery of HGF-expressing recombinant AAV improves muscle integrity and alleviates neurological symptoms in the nerve crush and SOD1-G93A transgenic mouse models. Biochemical and Biophysical Research Communications. 2019;517: 452&#x2013;7. Available from: doi: 10.1016/j.bbrc.2019.07.105</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2019.07.105</ArticleId><ArticleId IdType="pubmed">31376938</ArticleId></ArticleIdList></Reference><Reference><Citation>Molokotina YD, Boldyreva MA, Stafeev IS, Semina EV, Shevchenko EK, Zubkova ES, et al.. Combined action of GDNF and HGF up-regulates axonal growth by increasing ERK1/2 phosphorylation. Bulletin of Experimental Biology and Medicine. 2019;167: 413&#x2013;7. Available from: doi: 10.1007/s10517-019-04539-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10517-019-04539-4</ArticleId><ArticleId IdType="pubmed">31350657</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun W, Funakoshi H, Nakamura T. Overexpression of HGF retards disease progression and prolongs life span in a transgenic mouse model of ALS. Journal of Neuroscience. 2002;22: 6537&#x2013;48. Available from: doi: 20026634
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758174</ArticleId><ArticleId IdType="pubmed">12151533</ArticleId></ArticleIdList></Reference><Reference><Citation>Witt R, Weigand A, Boos AM, Cai A, Dippold D, Boccaccini AR, et al.. Mesenchymal stem cells and myoblast differentiation under HGF and IGF-1 stimulation for 3D skeletal muscle tissue engineering. BMC Cell Biology. 2017;18: 15. Available from: doi: 10.1186/s12860-017-0131-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12860-017-0131-2</ArticleId><ArticleId IdType="pmc">PMC5331627</ArticleId><ArticleId IdType="pubmed">28245809</ArticleId></ArticleIdList></Reference><Reference><Citation>Sufit RL, Ajroud-Driss S, Casey P, Kessler JA. Open label study to assess the safety of VM202 in subjects with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2017;18: 269&#x2013;78. Available from: doi: 10.1080/21678421.2016.1259334</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1259334</ArticleId><ArticleId IdType="pubmed">28166654</ArticleId></ArticleIdList></Reference><Reference><Citation>Warita H, Kato M, Asada R, Yamashita A, Hayata D, Adachi K, et al.. Safety, tolerability, and pharmacodynamics of intrathecal injection of recombinant human HGF (KP-100) in subjects with amyotrophic lateral sclerosis: A Phase I trial. Journal of Clinical Pharmacology. 2019;59: 677&#x2013;87. Available from: doi: 10.1002/jcph.1355</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcph.1355</ArticleId><ArticleId IdType="pubmed">30536581</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. 2000;1(5): 293&#x2013;9. Available from: doi: 10.1080/146608200300079536</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Thurmond B, Nakanishi A. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessment of respiratory function. MDNF ALS Study Group (Phase III). Journal of Neurological Science. 1999;169: 13&#x2013;21. Available from: doi: 10.1016/S0022-510X(99)00210-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris FH Jr, Calanchini PR, Fallat RJ, Panchari S, Jewett B. The administration of guanidine in amyotrophic lateral sclerosis. Neurology. 1974;24(8): 721&#x2013;8. Available from: doi: 10.1212/wnl.24.8.721</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.24.8.721</ArticleId><ArticleId IdType="pubmed">4858705</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson AG, Markhede I, Strang S, Persson LI. Well-being in patients with amyotrophic lateral sclerosis and their next of kin over time. Acta Neurologica Scandinavica. 2010;121: 244&#x2013;50. Available from: doi: 10.1111/j.1600-0404.2009.01191.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.2009.01191.x</ArticleId><ArticleId IdType="pubmed">20028340</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor AA, Fournier C, Polak M, Wang L, Zach N, Keymer M, et al.. Predicting disease progression in amyotrophic lateral sclerosis. Annals Clinical Translational Neurology. 2016;3(11): 866&#x2013;875. Available from: doi: 10.1002/acn3.348</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.348</ArticleId><ArticleId IdType="pmc">PMC5099532</ArticleId><ArticleId IdType="pubmed">27844032</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonker AH, Mills A, Lau LPL, Ando Y, Baroldi P, Bretz F, et al. Eds. Small population clinical trials: Challenges in the field of rare diseases. Report of the International Rare Diseases Research Consortium. 2016. https://www.irdirc.org/wp-content/uploads/2017/12/SPCT_Report.pdf</Citation></Reference><Reference><Citation>Barritault D, Gilbert-Sirieix M, Rice KL, Si&#xf1;eriz F, Papy-Garcia D, Baudouin C, et al.. RGTA&#xae; or ReGeneraTing Agents mimic heparan sulfate in regenerative medicine: from concept to curing patients. Glycoconjugates Journal. 2017;34(3): 325&#x2013;38. Available from: doi: 10.1007/s10719-016-9744-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10719-016-9744-5</ArticleId><ArticleId IdType="pmc">PMC5487810</ArticleId><ArticleId IdType="pubmed">27924424</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F, Zheng L, Cheng S, Peng Y, Fu L, Zhang X, et al.. Comparison of the interactions of different growth factors and glycosaminoglycans. Molecules. 2019;24(18): 3360. Available from: doi: 10.3390/molecules24183360</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules24183360</ArticleId><ArticleId IdType="pmc">PMC6767211</ArticleId><ArticleId IdType="pubmed">31527407</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazzarino G, Mangione R, Belli A, Di Pietro V, Nagy Z, Barnes NM, et al.. ILB&#xae; attenuates oxidative/nitrosative stress and mitochondrial dysfunction in patients with Amyotrophic Lateral Sclerosis. Journal of Personlized Medicine. 2021;11(8), 794. Available from: doi: 10.3390/jpm11080794</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm11080794</ArticleId><ArticleId IdType="pmc">PMC8399678</ArticleId><ArticleId IdType="pubmed">34442438</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons Z. Can we eliminate placebo in ALS clinical trials? Muscle Nerve. 2009; 39(6): 861&#x2013;865. Available from: doi: 10.1002/mus.21358</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.21358</ArticleId><ArticleId IdType="pubmed">19382170</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito D, Hashizume A, Hijikata Y, Yamada S, Iguchi Y, Iida M, et al.. Elevated serum creatine kinase in the early stage of sporadic amyotrophic lateral sclerosis. Journal of Neurology. 2019;266: 2952&#x2013;61. Available from: doi: 10.1007/s00415-019-09507-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09507-6</ArticleId><ArticleId IdType="pubmed">31456060</ArticleId></ArticleIdList></Reference><Reference><Citation>Raju NA, Rao SV, Joel JC, Jacob GG, Anil AK, Gowri SM, et al.. Predictive value of serum myoglobin and creatine phosphokinase for development of acute kidney injury in traumatic Rhabdomyolysis. Indian Journal of Critical Care Medicine. 2017;21(12): 852&#x2013;6. Available from: doi: 10.4103/ijccm.IJCCM_186_17</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijccm.IJCCM_186_17</ArticleId><ArticleId IdType="pmc">PMC5752795</ArticleId><ArticleId IdType="pubmed">29307967</ArticleId></ArticleIdList></Reference><Reference><Citation>Molnarfi N, Benkhoucha M, Funakoshi H, Nakamura T, Lalive PH. Hepatocyte growth factor: A regulator of inflammation and autoimmunity. Autoimmunity Reviews. 2015;14(4): 293&#x2013;303. Available from: doi: 10.1016/j.autrev.2014.11.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2014.11.013</ArticleId><ArticleId IdType="pubmed">25476732</ArticleId></ArticleIdList></Reference><Reference><Citation>Perdomo G, Martinez-Brocca MA, Bhatt BA, Brown NF, O&#x2019;Doherty RM, Garcia-Oca&#xf1;a A. Hepatocyte growth factor is a novel stimulator of glucose uptake and metabolism in skeletal muscle cells. Journal of Biological Chemistry. 2008;283(20): 13700&#x2013;6. Available from: doi: 10.1074/jbc.M707551200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M707551200</ArticleId><ArticleId IdType="pmc">PMC2376221</ArticleId><ArticleId IdType="pubmed">18362143</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandoorne T, De Bock K, Van Den Bosch L. Energy metabolism in ALS: an underappreciated opportunity? Acta Neuropathologica; 2018;135(4): 489&#x2013;509. Available from: doi: 10.1007/s00401-018-1835-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1835-x</ArticleId><ArticleId IdType="pmc">PMC5978930</ArticleId><ArticleId IdType="pubmed">29549424</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani S, Gordon R, Macmaw JK, Pfluger CMM, Henderson RD, Noakes PG, et al.. Elevation of the terminal complement activation products C5a and C5b-9 in ALS patient blood. Journal of Neuroimmunology; 2014;276: 213&#x2013;8. Available from: doi: 10.1016/j.jneuroim.2014.09.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2014.09.005</ArticleId><ArticleId IdType="pubmed">25262158</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson E, Lange S, Bergstr&#xf6;m T, Oshalim M, L&#xf6;nnroth I, Studahl M. (2018). Increased level of compleasomes in cerebrospinal fluid of patients with herpes simplex encephalitis Journal of Neurovirology. 2018;24: 702&#x2013;11. Available from: doi: 10.1007/s13365-018-0665-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13365-018-0665-x</ArticleId><ArticleId IdType="pmc">PMC6280959</ArticleId><ArticleId IdType="pubmed">30094629</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>